The use of extracorporeal shock waves for clinical applications was introduced in the United States more than 20 years ago; the first indication for use approved by FDA was for treatment of renal calculi (kideny stones). Since that time, the clinical applications of extracorporeal shock wave therapy (ESWT) have been expanded to include treatment of chronic proximal plantar fasciitis (P990086, HealthTronics OssaTron; P000048, Dornier EPOS Ultra; P040026, Orthospec Extracorporeal Shock Wave Device; P040039, Orthometrix Orbasone Pain Relief System) and chronic lateral epicondylitis (P990086/S003, HealthTronics OssaTron; P010039, Siemens Sonocur Basic). In addition, there are numerous reports in the clinical and pre-clinical literature of shockwave therapy used to treat orthopedic conditions such as fracture non-unions, femoral head necrosis, and non-orthopedic conditions related to tissue healing.